Knowledge guides

LG15: Dermatology treatments

Clinical sciences

Advanced Trainees will describe the principles of the foundational sciences.

View

Eligibility considerations

Advanced Trainees will assess the patient’s current condition and plan the next steps.

View

Less common or more complex patient considerations

Advanced Trainees will understand the resources that should be used to help manage patients.

View

Undertaking therapy

Advanced Trainees will monitor the progress of patients during the therapy.

View

Post therapy

Advanced Trainees will know how to monitor and manage patients post-therapy.

View

Important specific issues

Advanced Trainees will identify important specialty-specific issues and the impact of these on diagnosis and management, and integrate these into care.

View
  • Pathophysiology and complications of skin failure and other severe dermatoses
  • Pharmacotherapy
  • Photobiology

Clinical pharmacology of systemic drugs

  • Clinical pharmacology of:
    • injectables used in dermatology practice, including, but not limited to:
      • corticosteroids
      • local anaesthetics
    • topical drugs, covering absorption, clinical use, distribution, mechanism of action, and structure, including adverse effects, clinical indications, contraindications, and drug interactions, for specific topical therapies, including, but not limited to:
      • anti-infective agents
      • anti-inflammatory agent
      • cytotoxic drugs
      • emollients
      • immunomodulatory agents
      • keratolytics
      • photosensitisers
      • retinoids
  • Pharmacology, covering the absorption, clinical use, distribution, mechanism of action, metabolism and excretion, and structure, including adverse effects, clinical indications, contraindications, and drug interactions, for drugs used in dermatology, including, but not limited to:
    • antiandrogens
    • anti-infective agents
    • anti-inflammatory and immunomodulatory / suppressive
    • biologics
    • new and emerging drugs relevant to dermatology
    • psoralens
    • retinoids
    • targeted therapies

PCH

  • Altered pharmacodynamics and pharmacokinetics of medications in children
  • Eligibility for childhood vaccinations
  • Potential effects of medications on normal growth and development
  • Community Schedule of fully and partially funded pharmaceuticals Named Patient Pharmaceutical Assessment (NPPA) process
  • Patient decision making through provision of information regarding treatment choices
  • Pharmac initial and renewal funding criteria
  • Special authority
  • Unfunded medication availability in Aotearoa New Zealand, and current legislation regarding access
  • Issues around use of multiple immunosuppressive agents and off-label medications
  • Presentation and discussion of complex patients and treatment regimens at multidisciplinary meetings
  • Principles of treatment decisions for disorders with limited evidence-base
  • Appropriate laboratory, physical, and radiological monitoring of treatments prescribed or used
  • Management of acutely unwell dermatology patients:
    • investigation and management of causes and complications of skin failure and other severe dermatoses
  • Recognition and management of acute adverse drug reactions and anaphylaxis
  • Relevant disease assessment tools
  • Side effects of phototherapy, surgery, and other treatments
  • Value of shared decision making

PCH

  • Safe paediatric drug dose calculation
  • Clear guidance regarding follow-up requirements for patients and primary care providers
  • Management of acutely unwell dermatology patients:
    • recognition and management of acute adverse drug reactions and anaphylaxis
  • Prescribing per regulatory guidelines